Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Segment Reporting (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Schedule of Segment Reporting [Line Items]
Revenue
Operating expenses:
Research and development	1,632,581
General and administrative	10,279,981	1,275,095
Total operating expenses	11,912,562	1,275,095
Loss from operations	(11,912,562)	(1,275,095)
Other income (expense), net:
Realized gain on sale of digital assets	4,197,394
Trading gains, net	97
Unrealized gain on digital assets	1,812,348
Change in FV of derivative	55,146
Change in FV of warrant liability	22,377
Interest income	107,595	2,824
Interest expense	(283,011)	(117,719)
Foreign currency transaction loss	(521)
Total other income (expense), net	5,911,425	(114,895)
Net loss	(6,001,137)	$ (1,389,990)
BioBusiness Segment [Member]
Schedule of Segment Reporting [Line Items]
Revenue
Operating expenses:
Research and development	1,632,581
General and administrative	7,179,165
Total operating expenses	8,811,746
Loss from operations	(8,811,746)
Other income (expense), net:
Realized gain on sale of digital assets
Trading gains, net
Unrealized gain on digital assets
Change in FV of derivative
Change in FV of warrant liability
Interest income
Interest expense
Foreign currency transaction loss
Total other income (expense), net
Net loss	(8,811,746)
Digital Asset Segment [Member]
Schedule of Segment Reporting [Line Items]
Revenue
Operating expenses:
Research and development
General and administrative	3,100,816
Total operating expenses	3,100,816
Loss from operations	(3,100,816)
Other income (expense), net:
Realized gain on sale of digital assets	4,197,394
Trading gains, net	97
Unrealized gain on digital assets	1,812,348
Foreign currency transaction loss	(521)
Total other income (expense), net	6,009,317
Net loss	2,908,502
Corporate Segment [Member]
Schedule of Segment Reporting [Line Items]
Revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net:
Realized gain on sale of digital assets
Trading gains, net
Unrealized gain on digital assets
Change in FV of derivative	55,146
Change in FV of warrant liability	22,377
Interest income	107,595
Interest expense	(283,011)
Foreign currency transaction loss
Total other income (expense), net	(97,867)
Net loss	$ (97,867)

Apimeds Pharmaceuticals US, Inc. 10-K